Inhibition of cytochrome P450 enzymes by enrofloxacin in the sea bass (Dicentrarchus labrax)

被引:143
作者
Vaccaro, E
Giorgi, M
Longo, V
Mengozzi, G
Gervasi, PG
机构
[1] CNR, Ist Fisiol Clin, Area Ric, I-56100 Pisa, Italy
[2] Dipartimento Clin Vet, I-56124 Pisa, Italy
关键词
cytochrome P450 inhibition; sea bass; enrofloxacin metabolism;
D O I
10.1016/S0166-445X(02)00064-4
中图分类号
Q17 [水生生物学];
学科分类号
071004 ;
摘要
Currently, there are no reports on the effects of enrofloxacin (EF), a fluoroquinolone antibiotic, on the cytochrome P450 enzymes in fish, although its use as antimicrobial agent in aquaculture has been put forward. Therefore, the in vivo and in vitro effects of EF on hepatic P450 enzymes of sea bass, a widespread food-producing fish, have been evaluated. Sea bass pretreated with a single dose of EF (3 mg/kg i.p.) or with three daily doses of EF (1 mg/kg i.p.) markedly depressed the microsomal N-demethylation of aminopyrine, erythromycin, the O-deethylation of 7-ethoxycoumarin, ethoxyresorufin and the 6beta-testosterone hydroxylase. In vitro experiments showed that EF at 10 muM inhibited the above-mentioned activities and, in particular, the erythromycin N-demethylase (ERND) and 6beta-testosterone-hydroxylase, likely dependant on a P450 3A isoform. When the nature of ERND inhibition by EF was specifically studied with sea bass liver microsomes, it was found that EF is a potent mechanism-based inhibitor, with K-i of 3.7 muM and a K-intact of 0.045 min(-1). An immunoblot analysis with anti P450 3A27 of trout showed that the P450 3A isoform, constitutively expressed in sea bass, is particularly susceptible to inactivation by EF. In vitro experiments with sea bass microsomes have also demonstrated that EF is oxidative deethylated by the P450 system to ciprofloxacin (CF) and that this compound maintains the ability to inactivate the P450 enzymes. The mechanism by which EF or CF inactivate the P450 enzymes has not been studied but an attack of P450 on the cyclopropan ring, present, both in EF and CF structure, with the formation of electrophilic intermediates (i.e. radicals) has been postulated. In conclusion, the EF seems to be a powerful inhibitor of P450s in the sea bass. Therefore, the clinical use of this antibiotic in aquaculture has to be considered with caution. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 30 条
[1]   KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9 [J].
BALDWIN, SJ ;
BLOOMER, JC ;
SMITH, GJ ;
AYRTON, AD ;
CLARKE, SE ;
CHENERY, RJ .
XENOBIOTICA, 1995, 25 (03) :261-270
[2]  
BERGAN T, 1988, INFECTION S1, V16, P3
[3]   Fluoroquinolones in animal health [J].
Brown, SA .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1996, 19 (01) :1-14
[4]  
FUHR U, 1990, DRUG METAB DISPOS, V18, P1005
[5]   The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck [J].
Intorre, L ;
Mengozzi, G ;
Bertini, S ;
Bagliacca, M ;
Luchetti, E ;
Soldani, G .
VETERINARY RESEARCH COMMUNICATIONS, 1997, 21 (02) :127-136
[6]   Pharmacokinetics of enrofloxacin in the seabass (Dicentrarchus labrax) [J].
Intorre, L ;
Cecchini, S ;
Bertini, S ;
Varriale, AMC ;
Soldani, G ;
Mengozzi, G .
AQUACULTURE, 2000, 182 (1-2) :49-59
[7]   SELECTIVE INDUCTION OF RENAL MICROSOMAL CYTOCHROME-P-450-LINKED MONOOXYGENASES BY 1,1-DICHLOROETHYLENE IN MICE [J].
KRIJGSHELD, KR ;
GRAM, TE .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (12) :1951-1956
[8]   Identification and characterization of a cDNA encoding cytochrome P450 3A from the fresh water teleost medaka (Oryzias latipes) [J].
Kullman, SW ;
Hamm, JT ;
Hinton, DE .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (01) :29-38
[9]   CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].
LAEMMLI, UK .
NATURE, 1970, 227 (5259) :680-+
[10]   Pharmacokinetics of enrofloxacin in the red pacu (Colossoma brachypomum) after intramuscular, oral and bath administration [J].
Lewbart, G ;
Vaden, S ;
Deen, J ;
Manaugh, C ;
Whitt, D ;
Doi, A ;
Smith, T ;
Flammer, K .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1997, 20 (02) :124-128